Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURITY: Preoperative GAP Chemotherapy vs Upfront Surgery in High-Risk Resectable Biliary Tract Cancers
NCT06037980Phase 3Recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Nov 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in biliary tract cancer (BTC) (2 arms), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoints: 12-month Progression-Free Survival rate and Median Progression-Free Survival up to 120 months. Started Nov 2023; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06037980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037980.